tirzepatide off label Pharmacists Play Central Role in Optimizing Use for Type 2 Diabetes FDA approves new version of

Emotional eating triggers and grazing behaviors frequently resurface

Nilsson O, Bilchik AJ, Goldenring JR, Ballantyne GH, Adrian TE, and Modlin IM

Heres what it means for Medicaid enrollees: Medicaid access through the BALANCE Model could begin as early as May 2026 States must opt in voluntarily its not automatic Participating states receive federally negotiated prices from Eli Lilly (Zepbound, Mounjaro) and Novo Nordisk (Wegovy, Ozempic) Wegovy and Zepbound starting doses would cost the program $350/month (reduced from over $1,000) Patients in participating states would pay $50/month for covered GLP-1s Prior authorization and qualifying criteria will still apply This is the biggest potential expansion of GLP-1 access for Medicaid enrollees in history but it depends on your state deciding to participate

Appetite Suppression: The central nervous system perceives a longer sense of fullness, leading to a reduced caloric intake

Thats why its important to use Wegovy under the guidance of a healthcare provider who can monitor your response and adjust your treatment if needed

Tolerance for side effects: What side effects are you willing to manage